ESC-HFA 2023: Late-Breaking Science Video Collection
Published: 23 May 2023
-
Views:
2906
-
Likes:
7
-
Views:
2906
-
Likes:
7
-
Up Next -
3m 50sPart 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Harriette Van Spall, Tariq Ahmad, Jozine ter Maaten
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial Harriette Van Spall, Robert Mentz
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Harriette Van Spall, James L Januzzi
-
4m 3sPart 1 | Session 4 TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction James L Januzzi, Harriette Van Spall
-
2m 45sPart 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Jasper J Brugts
-
6m 54sPart 2 | Session 2 REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Ahmad Masri
-
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Marianna Fontana
-
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Ankeet Bhatt
-
8m 47sPart 2 | Session 5 DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF Domingo Figal
-
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients Niklas Dyrby Johansen
-
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF Ross Campbell
-
5m 11sPart 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure Stephen J Greene
Overview
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
More from this programme
Part 1
Late-breaker Discussions with Dr Van Spall
Part 2
Expert Interviews
About the episode
Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
Interview Questions:
1. What is the background of this study?
2. What is the definition of heart failure in 2023?
3. Could you provide details about the study's methodology and the characteristics of the patient cohort?
4. What are the findings?
5. To what extent can these findings be generalised or applied to patients in different healthcare systems?
6. What are the take home messages for practice?
Faculty Biographies
John GF Cleland
Professor of Cardiology
Prof John Cleland is a Professor of Cardiology at University of Glasgow, Glasgow, UK.
In 1977, he qualified from the University of Glasgow, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation.
His main interests include heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines.
He founded the European Journal of Heart Failure and is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure.
Comments